ProCE Banner Activity

ALTERNATIVE: Dual HER2 Blockade + Aromatase Inhibitor in Postmenopausal Women With HER2+, HR+ MBC

Slideset Download
Conference Coverage
Significantly improved PFS and ORR observed with addition of lapatinib to trastuzumab plus investigator-selected aromatase inhibitor.

Released: June 06, 2017

Expiration: June 05, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology